LONG TERM FOLLOW-UP OF PATIENTS WITH ADRENAL INCIDENTALOMAS AND SUBCLINICAL HY珀CORTISOLISM: A SINGLE CENTER EXPERIENCE

UNIVERSITY OF BELGRADE
SCHOOL OF MEDICINE

M. Ivović, Lj. Marina, M. Tančić-Gajić,
Z. Arizanović, J Milin-Layović, D Raković, Z Stojanović,
A Paunović, S Vujović

Clinic for Endocrinology,
diabetes and metabolic disease, Clinical Center Serbia
School of Medicine

Introduction:
It has been more than 70 years since the first adrenal incidentalomas (AI) were described. Most of these tumors are non-secreting, and are found in 4-7% of adult population. Patients with subclinical hypercortisolism (or autonomous cortisol secretion) (SH) are observed in 1-29% of patients with AIs. Evidence suggests that this condition may be associated with higher prevalence of diabetes, obesity, hypertension and osteoporosis.

Patients:
Between 1999 and 2015, 857 patients with AI were evaluated. Seventy-two patients were diagnosed with SH based on two out of three criteria: 1mg overnight dexamethasone cortisol >83nmol/l, low basal ACTH (below 14ng/l) and lack of diurnal cortisol rhythm (midnight cortisol >150nmol/l). Fifty-nine women and thirteen men, mean age 58.37±8.25 years and mean BMI 28.91±5.19 kg/m2. Thirty-seven (51.38%) patients had bilateral tumors and thirty-five (48.61%) had unilateral tumors, mean tumor size was 37.91±10.88mm and mean follow-up was 5.02±2.98 years.

At admission 59 patients (81.94%) had hypertension, 20(27.7%) had glucose intolerance, 18(25%) had diabetes and 20 (27.75%) had osteoporosis, 14 patients (19.44%) already suffered cardiovascular events (nine had myocardial infarction and one had a stroke).

Results:
During the follow-up period one patient (1.38%) had a stroke, one (1.38%) developed diabetes, five (6.94%) developed glucose intolerance and one (1.38%) patient decreased bone mineral density to osteoporotic levels. Three patients underwent surgery due to tumor growth. Pathohistology showed cortical adenoma.

Conclusion:
During the average follow-up of 5 years of seventy-two patients with SH and AI, 1.38% have had a new cardiovascular event, but nearly 7% developed glucose intolerance which is important when deciding about the optimal management and follow-up strategies.